Next Article in Journal
Xylan Decomposition in Plant Cell Walls as an Inducer of Surfactin Synthesis by Bacillus subtilis
Next Article in Special Issue
Discovery and Characterization of an ALFA-Tag-Specific Affinity Resin Optimized for Protein Purification at Low Temperatures in Physiological Buffer
Previous Article in Journal
Bone Health in Aging Men: Does Zinc and Cuprum Level Matter?
Previous Article in Special Issue
Nanobody-Based Indirect Competitive ELISA for Sensitive Detection of 19-Nortestosterone in Animal Urine
Review

The Application of Nanobody in CAR-T Therapy

1
Shenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, China
2
Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, China
3
Department of Immunology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453000, China
*
Author to whom correspondence should be addressed.
Academic Editor: Nick Devoogdt
Biomolecules 2021, 11(2), 238; https://doi.org/10.3390/biom11020238
Received: 5 December 2020 / Revised: 25 January 2021 / Accepted: 1 February 2021 / Published: 8 February 2021
(This article belongs to the Special Issue The Therapeutic and Diagnostic Potential of Nanobodies)
Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks. View Full-Text
Keywords: nanobody; VHH; CAR-T; BCMA nanobody; VHH; CAR-T; BCMA
Show Figures

Figure 1

MDPI and ACS Style

Bao, C.; Gao, Q.; Li, L.-L.; Han, L.; Zhang, B.; Ding, Y.; Song, Z.; Zhang, R.; Zhang, J.; Wu, X.-H. The Application of Nanobody in CAR-T Therapy. Biomolecules 2021, 11, 238. https://doi.org/10.3390/biom11020238

AMA Style

Bao C, Gao Q, Li L-L, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu X-H. The Application of Nanobody in CAR-T Therapy. Biomolecules. 2021; 11(2):238. https://doi.org/10.3390/biom11020238

Chicago/Turabian Style

Bao, Chaolemeng, Quanli Gao, Lin-Lin Li, Lu Han, Bingxiang Zhang, Yijin Ding, Zongpei Song, Ruining Zhang, Jishuai Zhang, and Xian-Hui Wu. 2021. "The Application of Nanobody in CAR-T Therapy" Biomolecules 11, no. 2: 238. https://doi.org/10.3390/biom11020238

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop